First Time Loading...

Halozyme Therapeutics Inc
NASDAQ:HALO

Watchlist Manager
Halozyme Therapeutics Inc Logo
Halozyme Therapeutics Inc
NASDAQ:HALO
Watchlist
Price: 40.3 USD 1.21% Market Closed
Updated: May 4, 2024
HALO
/
Income Statement
/
Revenue

Halozyme Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Halozyme Therapeutics Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Halozyme Therapeutics Inc
NASDAQ:HALO
Revenue
$829.3m
CAGR 3-Years
46%
CAGR 5-Years
40%
CAGR 10-Years
31%
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

Halozyme Therapeutics Inc
Revenue Breakdown

Breakdown by Geography
Halozyme Therapeutics Inc

Total Revenue: 829.3m USD
100%
United States: 587.2m USD
70.8%
Switzerland: 149m USD
18%
Belgium: 58.4m USD
7%
All Other Foreign: 19.6m USD
2.4%
Japan: 15.1m USD
1.8%
Show More
Show Less

Breakdown by Segments
Halozyme Therapeutics Inc

Total Revenue: 829.3m USD
100%
Royalties: 447.9m USD
54%
Product Sales, Net: 300.9m USD
36.3%
Revenues Under Collaborative Agreements: 80.5m USD
9.7%
Sale Of Device Partnered Products: 54.6m USD
6.6%
Show More
Show Less

See Also

What is Halozyme Therapeutics Inc's Revenue?
Revenue
829.3m USD

Based on the financial report for Dec 31, 2023, Halozyme Therapeutics Inc's Revenue amounts to 829.3m USD.

What is Halozyme Therapeutics Inc's Revenue growth rate?
Revenue CAGR 10Y
31%

Over the last year, the Revenue growth was 26%. The average annual Revenue growth rates for Halozyme Therapeutics Inc have been 46% over the past three years , 40% over the past five years , and 31% over the past ten years .

ALPHA SPREAD
Join more than 133,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.